Related Experiment Video

Updated: Aug 24, 2026

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay
11:41

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

Published on: March 10, 2015

Experimental approaches to TSE prevention via inhibition of prion formation

Galatia Politopoulou1

  • 1Department of Rheumatology, Avon Orthopaedic Centre, Southmead Hospital, University of Bristol. g.politopoulou@bristol.ac.uk

Protein and Peptide Letters
|June 9, 2004
PubMed

Insights

Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative diseases. Research focuses on inhibiting prion protein conversion as a potential therapeutic strategy for these unique, complex conditions.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Protein Chemistry

Background:

  • Transmissible spongiform encephalopathies (TSEs) are fatal diseases affecting the central nervous system.
  • TSEs can be inherited, infectious, or spontaneous.
  • The key pathogenic agent is a misfolded prion protein (PrPSc), distinct from the normal cellular prion protein (PrPc).

Purpose of the Study:

  • To explore the mechanism of prion protein conversion.
  • To identify compounds that inhibit PrPSc formation.
  • To propose potential therapeutic strategies for TSEs.

Main Methods:

  • Investigating the conformational changes of prion proteins.
  • Assessing the inhibitory effects of various compounds on PrPc to PrPSc conversion.
  • Analyzing the biochemical properties of PrPSc, including beta-sheet content and protease resistance.

Main Results:

  • Prion protein conversion involves the templating of normal PrPc by abnormal PrPSc seeds.
  • Certain compounds demonstrate the ability to inhibit this conversion process.
  • PrPSc exhibits high beta-sheet content and resistance to enzymatic degradation.

Conclusions:

  • Inhibiting the conversion of PrPc to PrPSc is a promising therapeutic avenue for TSEs.
  • Understanding prion protein misfolding is crucial for developing effective treatments.
  • Further research into anti-prion compounds may lead to novel TSE therapies.

More Related Videos

Prion Safety Laboratory Swipe Test06:01

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

Protein Misfolding Cyclic Amplification of Prions10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...